Evidence map›Paper›PMID 37895858›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?

Rohit Tayal, Sabina Yasmin, Samrat Chauhan, Thakur Gurjeet Singh, Monika Saini, Eman Shorog, Maryam M Althubyani, Baiaan H Alsaadi, Fatimah Aljohani, Maram A Alenazi and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Atherogenic Effect of Homocysteine, a Biomarker of Inflammation and Its Treatment.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Rohit TayalChitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India.
Sabina YasminDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.
Samrat ChauhanChitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India.ORCID 0000-0003-4120-6534
Thakur Gurjeet SinghChitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India.
Monika SainiM.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala 133207, Haryana, India.
Eman ShorogClinical Pharmacy Department, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.ORCID 0000-0003-0763-1510
Maryam M AlthubyaniDepartment of Clinical Services, Pharmaceutical Care Services, King Salman Medical City, Ministry of Health MOH, Al Madinah Al Munawwarah 11176, Saudi Arabia.
Baiaan H AlsaadiDepartment of Clinical Services, Pharmaceutical Care Services, King Salman Medical City, Ministry of Health MOH, Al Madinah Al Munawwarah 11176, Saudi Arabia.
Fatimah AljohaniPrince Sultan Armed Forces Hospital, Al Madenah Al Monwarah 42375, Saudi Arabia.
Maram A AlenaziPharmaceutical Care Services, King Salman Specialist Hospital, Ministry of Health (MOH), Hail 55471, Saudi Arabia.
Sarah A AbutailyAmbulatory Care Clinical, Prince Sultan Military Medical City, Riyadh 12233, Saudi Arabia.
Mohammad Yousuf AnsariM.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala 133207, Haryana, India.ORCID 0000-0001-6365-7104
Chitkara University · INMinistry of Health · SAKing Khalid University · SAMaharishi Markandeshwar University, Mullana · INArmed Forces Hospital · SARiyadh Armed Forces Hospital · SA

Funding

King Khalid University RGP. 1/219/44
6 · The paper itself

Abstract

Balancing the therapeutic advantages of a medicine with its possible risks and side effects is an important part of medical practice and drug regulation. When a drug is designed to treat a particular disease or medical condition ends up causing additional risks or side effects that lead to the development of other serious health problems, it can have detrimental consequences for patients. This article explores the correlation between persistent proton pump inhibitor (PPI) use and hypertension, a common cardiovascular ailment. While PPIs are beneficial in treating various gastrointestinal problems, their availability without a prescription has resulted in self-medication and long-term use without medical monitoring. Recent findings have revealed a link between long-term PPI usage and increased cardiovascular risks, particularly hypertension. This study investigates the intricate mechanisms underlying PPI's effects, focusing on potential pathways contributing to hypertension, such as endothelial dysfunction, disruption of nitric oxide bioavailability, vitamin B deficiency, hypocalcemia, and hypomagnesemia. The discussion explains how long-term PPI use can disrupt normal endothelial function, vascular control, and mineral balance, eventually leading to hypertension. The article emphasizes the significance of using PPIs with caution and ongoing research to better understand the implications of these medications on cardiovascular health.

Indexed as

adverse effectsendothelial dysfunctionhypertensionhypocalcemiaProton Pump Inhibitor

Identifiers

PMID37895858
PMCPMC10609986
OpenAlexW4387235066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.